# OnCo record aaml1031 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/aaml1031/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "aaml1031", "NCT01371981" ;
  schema:name "AAML1031"@en ;
  schema:alternateName "COG AAML1031"@en ;
  schema:description "AAML1031 was the children's leukaemia trial that found adding bortezomib to standard chemotherapy did not help and caused more nerve damage, while a separate part of the trial suggested that adding the FLT3 blocker sorafenib does improve outcomes for children whose leukaemia carries a high load of the FLT3-ITD mutation."@en ;
  schema:url <https://onco.cc/trials/aaml1031/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01371981> ;
  onco:status "mixed" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/aml-paediatric/>, <https://onco.cc/cancers/aml-flt3/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/leukaemia/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/sorafenib/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-aaml1031-bortezomib-aplenc-haematologica-2020/>, <https://onco.cc/key-papers/paper-aaml1031-sorafenib-flt3-pollard-jco-2022/> .